| Date |
Title (click to read) |
| May 8, 2008 |
GATTEX(TM) Abstracts Accepted for Presentation at DDW Conference; Phase 3 Short Bowel Syndrome Results Scheduled for Oral Plenary Session |
| May 7, 2008 |
NPS Pharmaceuticals Reports First Quarter 2008 Financial Results and Business Update |
| April 29, 2008 |
NPS Pharmaceuticals to Report First Quarter 2008 Financial Results |
| March 17, 2008 |
NPS Reports Successful GATTEX(TM) Extension Study |
| March 13, 2008 |
NPS Pharmaceuticals Reports 2007 Financial Results |
| March 6, 2008 |
NPS Pharmaceuticals to Report 2007 Financial Results |
| February 29, 2008 |
NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference |
| February 26, 2008 |
NPS Pharmaceuticals Announces Senior Management Changes |
| February 4, 2008 |
NPS Pharmaceuticals to Present at BIO CEO & Investor Conference |
| January 30, 2008 |
NPS Pharmaceuticals Announces Board Appointments |
| January 28, 2008 |
NPS Pharmaceuticals Provides Update on GATTEX(TM) Clinical Development in Short Bowel Syndrome |
| January 2, 2008 |
NPS Pharmaceuticals Appoints Dr. Alan G. Harris Chief Medical Officer |
| December 21, 2007 |
NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008 |
| November 13, 2007 |
NPS Pharmaceuticals Announces Senior Management Appointments |
| November 2, 2007 |
NPS Pharmaceuticals to Webcast Presentation at CIBC World Markets 18th Annual Healthcare Conference |
| November 1, 2007 |
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance |
| October 31, 2007 |
Nycomed Confirms Commitment to GATTEX(TM) Partnership; NPS to Receive $25 Million Payment |
| October 30, 2007 |
NPS Pharmaceuticals Names Douglas N. Dobak Vice President of Regulatory Affairs and Drug Safety |
| October 25, 2007 |
NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007 |
| October 25, 2007 |
NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan |
| October 18, 2007 |
NPS Pharmaceuticals Announces Results of Tender Offer |
| October 11, 2007 |
Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study |
| October 9, 2007 |
NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development |
| October 8, 2007 |
NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer |
| October 3, 2007 |
NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007 |
| September 26, 2007 |
NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America |
| September 19, 2007 |
PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism |
| September 6, 2007 |
NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 |
| August 7, 2007 |
NPS Pharmaceuticals Raises $200 Million to Retire Debt, Reports Second Quarter Financial Results and Revises Guidance |
| August 7, 2007 |
NPS Pharmaceuticals Completes $100 Million Series B Note Offering Backed by Sensipar(R) Royalties |
| August 7, 2007 |
NPS Pharmaceuticals Announces $50 Million Convertible Note Sale |
| July 19, 2007 |
NPS Announces Legal Staff Changes |
| July 16, 2007 |
NPS Pharmaceuticals Announces Sale of Preotact(R) Royalty to Drug Royalty Corporation (DRC) |
| July 12, 2007 |
NPS Pharmaceuticals to Report Second Quarter 2007 Financial Results on August 7, 2007 |
| July 9, 2007 |
NPS Pharmaceuticals Expands Agreement with European Partner Nycomed to Include Broader Territory Rights for Preotact(R) |
| July 3, 2007 |
NPS Appoints Francois Nader, M.D., to Executive Vice President and COO |
| July 3, 2007 |
NPS Pharmaceuticals Announces Sale of Two Facilities |
| June 19, 2007 |
NPS Pharmaceuticals to Webcast Presentation at Jefferies Healthcare Conference |
| June 11, 2007 |
NPS Pharmaceuticals to Webcast Presentation at Goldman Sachs 28th Annual Global Healthcare Conference |
| June 4, 2007 |
NPS Announces Progression of the Calcilytics Development Program in Osteoporosis by GlaxoSmithKline |
| May 9, 2007 |
NPS Reports First Quarter 2007 Financial Results and Progress in Executing New Business Plan, Reiterates Guidance |
| May 3, 2007 |
NPS Pharmaceuticals to Report First Quarter 2007 Financial Results |
| April 24, 2007 |
NPS Pharmaceuticals to Webcast Presentation at Citigroup Global Healthcare Conference |
| March 14, 2007 |
NPS Pharmaceuticals Reports 2006 Results and Progress, Announces New Business Plan to Advance Pipeline |
| March 12, 2007 |
NPS Pharmaceuticals to Webcast Presentation at Lehman Brothers Global Healthcare Conference |
| February 20, 2007 |
NPS Pharmaceuticals to Report Fourth Quarter and Year-end Financial Results |
| November 8, 2006 |
NPS Pharmaceuticals Reports Third Quarter and Nine Month Results |
| October 13, 2006 |
NPS Pharmaceuticals to Report Third Quarter 2006 Financial Results |
| August 3, 2006 |
NPS Pharmaceuticals Reports Second Quarter and Six Month Operating Results |
| July 18, 2006 |
NPS Pharmaceuticals to Report Second Quarter 2006 Financial Results |
| July 14, 2006 |
NPS Pharmaceuticals Named in Securities Class Action Lawsuit |
| June 21, 2006 |
NPS Pharmaceuticals to Webcast Presentation at Jefferies Life Sciences Conference |
| June 12, 2006 |
NPS Announces Aggressive Plan to Restructure Operations and Cut Costs |
| June 6, 2006 |
NPS Pharmaceuticals to Webcast Presentation at Goldman Sachs 27th Annual Global Healthcare Conference |
| June 6, 2006 |
NPS Pharmaceuticals Appoints Francois Nader, MD, MBA, Chief Medical and Commercial Officer |
| May 12, 2006 |
NPS Elects N. Anthony Coles, M.D. Chief Executive Officer |
| May 11, 2006 |
Teduglutide Abstract Selected for Late-Breaking Session at Digestive Disease Week 2006 |
| May 2, 2006 |
NPS Pharmaceuticals Reports First Quarter 2006 Operating Results |
| May 2, 2006 |
NPS Announces Clinical Advancement of Calcilytics Program by Its Collaborator GlaxoSmithKline |
| April 28, 2006 |
NPS Pharmaceuticals to Webcast Presentation at Morgan Stanley Healthcare Unplugged Conference |
| April 26, 2006 |
European Commission Issues Marketing Authorization for Preotact(R) (PREOS(R)) |
| April 24, 2006 |
NPS Names Juergen Lasowski, Ph.D., Senior Vice President of Corporate Development |
| April 24, 2006 |
NPS Pharmaceuticals to Report First Quarter 2006 Financial Results |
| April 17, 2006 |
NPS Pharmaceuticals to Webcast Presentation at UBS Global Specialty Pharmaceuticals Conference |
| March 29, 2006 |
NPS Updates Status of PREOS(R) NDA |
| March 10, 2006 |
NPS Receives Approvable Letter for PREOS NDA |
| February 27, 2006 |
NPS to Advance Clinical Development of Teduglutide as Treatment for Crohn's Disease |
| February 23, 2006 |
CHMP Recommends Authorization to Market Preotact(R) (PREOS(R)) in Europe |
| February 16, 2006 |
NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating Results |
| February 8, 2006 |
NPS Announces Extension of R&D Collaboration With AstraZeneca |
| January 31, 2006 |
NPS Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results |
| January 25, 2006 |
NPS Files Shelf Registration Statement Under New SEC Rules, Retires Previous Shelf Registration Statement |
| January 4, 2006 |
NPS Pharmaceuticals to Webcast Presentation at 24th Annual JP Morgan Healthcare Conference |
| November 4, 2005 |
NPS Pharmaceuticals Reports Third Quarter and Nine Month Results |
| November 2, 2005 |
Event Update: NPS Pharmaceuticals to Report Third Quarter Financial Results at 10:00 a.m. EST on November 4, 2005 |
| November 1, 2005 |
N. Anthony Coles, M.D., M.P.H., Joins NPS Pharmaceuticals as Chief Operating Officer and Successor to CEO Hunter Jackson, Ph.D. |
| October 28, 2005 |
NPS Pharmaceuticals to Report Third Quarter Financial Results |
| October 24, 2005 |
NPS Pharmaceuticals to Promote Allergan's RESTASIS(R) to Rheumatologists in the United States |
| September 27, 2005 |
Event Time Correction: NPS Pharmaceuticals to Webcast Investment Community Meeting at American Society for Bone and Mineral Research Conference at 11:30 Central Time Today |
| September 27, 2005 |
New Analyses Show PREOS(R) Improves Bone Strength and Reduces Fracture Risk in Postmenopausal Women With Osteoporosis |
| September 23, 2005 |
NPS Pharmaceuticals to Webcast Investment Community Meeting at American Society for Bone and Mineral Research Conference |
| September 8, 2005 |
NPS Pharmaceuticals Announces Planned Sale of Common Stock |
| August 23, 2005 |
NPS Pharmaceuticals Files Shelf Registration Statement |
| August 18, 2005 |
Medical Journal Reports Teduglutide Improves Intestinal Function in Patients With Short Bowel Syndrome |
| August 10, 2005 |
Year-Two PaTH Data Demonstrate Benefit of Sequential Therapy for Osteoporosis |
| July 26, 2005 |
NPS Pharmaceuticals Reports Second Quarter and Six Month Operating Results |
| July 19, 2005 |
NPS Pharmaceuticals to Report Second Quarter Financial Results |
| July 11, 2005 |
PREOS(R) New Drug Application Accepted for Review by FDA |
| May 10, 2005 |
NPS Pharmaceuticals Reports First Quarter 2005 Operating Results |
| May 3, 2005 |
NPS Pharmaceuticals to Report First Quarter Financial Results |
| April 7, 2005 |
New TOP Study Data Analyses of PREOS Show Improved Bone Microarchitecture and Reduction in Vertebral Fractures in Postmenopausal Osteoporotic Patients |
| March 30, 2005 |
NPS Announces Start of Preotact(TM) Regulatory Review in Europe |
| March 8, 2005 |
NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating Results |
| March 3, 2005 |
NPS Pharmaceuticals and Ventiv Health Announce the Launch of a Specialty Sales Force |
| March 1, 2005 |
NPS Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results |
| February 7, 2005 |
NPS Provides Update on PREOS(R) NDA Process and Timing |
| December 23, 2004 |
NPS Pharmaceuticals Announces Conference Call and Webcast to Be Held Today |
| December 23, 2004 |
NPS Completes $175 Million Note Offering Backed by Sensipar(R) Royalties |
| December 16, 2004 |
NPS Names Michael Bonney and Rachel Selisker to Its Board of Directors |
| November 30, 2004 |
NPS Preparing Expanded PREOS(R) NDA Package to Be Submitted in February 2005 |
| November 8, 2004 |
NPS Pharmaceuticals Reports Third Quarter and Nine Month Results |
| November 8, 2004 |
Reminder - NPS Pharmaceuticals to Report Third Quarter and Nine Month Operating Results |
| November 1, 2004 |
NPS Pharmaceuticals to Report Third Quarter and Nine Month Operating Results |
| October 21, 2004 |
NPS Pharmaceuticals Presents Additional TOP Study Data at ACR |
| October 19, 2004 |
NPS Pharmaceuticals to Discuss Top Study Results at ACR Scientific Meeting |
| October 14, 2004 |
Reminder - NPS Pharmaceuticals Third Annual Investor/Analyst Meeting 2004 |
| October 12, 2004 |
NPS Pharmaceuticals Third Annual Investor/Analyst Meeting 2004 |
| October 11, 2004 |
NPS Reports Inconclusive Results of Acute Migraine Study |
| October 4, 2004 |
NPS Pharmaceuticals Announces Positive Results of Three PREOS Trials at ASBMR |
| September 30, 2004 |
NPS Pharmaceuticals to Host Meeting for the Investment Community and Webcast at the American Society of Bone and Mineral Research Conference |
| September 27, 2004 |
NPS Announces Presentation of Top Study Data at Rheumatology Meetings |
| August 9, 2004 |
NPS Pharmaceuticals to Promote Amgen's Kineret(R) to Rheumatologists |
| August 9, 2004 |
NPS Pharmaceuticals Reports Second Quarter and Six Month Operating Results |
| August 2, 2004 |
NPS Pharmaceuticals to Report Second Quarter and Six Month Operating Results |
| May 26, 2004 |
NPS Pharmaceuticals Celebrates Tenth Anniversary of IPO and Nasdaq Market Listing |
| May 6, 2004 |
NPS Pharmaceuticals Reports First Quarter 2004 Results |
| April 29, 2004 |
NPS Pharmaceuticals to Report First Quarter Financial Results |
| April 26, 2004 |
NPS Appoints Pharmaceutical Executives to Commercial Team |
| April 21, 2004 |
NPS Pharmaceuticals and Nycomed Announce US$90+ Million PREOS(R) Marketing Agreement for Europe |
| April 6, 2004 |
NPS Pharmaceuticals Begins Pivotal Study With Teduglutide in Patients With Short Bowel Syndrome |
| March 30, 2004 |
NPS Announces Positive Phase III Study Results for PREOS(R) in Women With Osteoporosis |
| March 29, 2004 |
NPS Pharmaceuticals to Host PREOS Study Results Conference Call on March 30, 2004 |
| March 8, 2004 |
NPS Pharmaceuticals Announces Approval of Sensipar(TM) by U.S. FDA |
| February 10, 2004 |
NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating Results |
| February 10, 2004 |
Reminder - NPS Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results |
| February 3, 2004 |
NPS Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results |
| February 2, 2004 |
NPS Pharmaceuticals to Speak and Webcast Presentation at Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference |
| January 26, 2004 |
NPS Pharmaceuticals to Webcast Presentation At US Bancorp Piper Jaffray Healthcare Conference |
| January 13, 2004 |
NPS Pharmaceuticals to Speak and Webcast Presentation AT 22nd Annual JP Morgan Healthcare Conference |
| December 16, 2003 |
NPS Begins Clinical Trial in Migraine, Appoints Chief Medical Officer |
| November 20, 2003 |
NPS Reports Positive PREOS Study Results |
| November 19, 2003 |
NPS Pharmaceuticals to Report Results of PREOS Carcinogenicity Study |
| November 6, 2003 |
NPS Pharmaceuticals Reports Third Quarter and Nine Month Operating Results |
| October 30, 2003 |
NPS Pharmaceuticals to Report Third Quarter and Nine Month 2003 Financial Results |
| October 7, 2003 |
NPS Pharmaceuticals Announces Completion of Top Study Dosing, Launch of Crohn's Trial |
| September 20, 2003 |
NPS Comments on Interim Results of PaTH Study Data |
| September 8, 2003 |
NPS Pharmaceuticals Announces NDA Filing by Amgen for Cinacalcet HCL |
| August 12, 2003 |
NPS Pharmaceuticals Reports Second Quarter and Six Month Operating Results |
| August 5, 2003 |
NPS Pharmaceuticals to Report Second Quarter And Six Month 2003 Financial Results |
| July 22, 2003 |
NPS Pharmaceuticals Announces Settlement of Claim Against Forest Laboratories |
| July 9, 2003 |
NPS Pharmaceuticals Announces Exercise of Option to Purchase an Additional $22 Million of Its 3.0% Convertible Debt |
| June 11, 2003 |
NPS Pharmaceuticals Announces Pricing of $170 Million Convertible Debt Offering |
| June 11, 2003 |
NPS Pharmaceuticals Announces Proposed Convertible Debt Offering |
| June 4, 2003 |
NPS Pharmaceuticals Announces Corporate Presentations on Friday, June 6 and Thursday, June 12 |
| June 4, 2003 |
NPS Pharmaceuticals and Enzon Pharmaceuticals Announce Mutual Termination of Merger Agreement |
| May 14, 2003 |
NPS Pharmaceuticals Reports First Quarter 2003 Results |
| May 7, 2003 |
NPS Pharmaceuticals To Report First Quarter 2003 Financial Results |
| April 23, 2003 |
NPS Reports Announcement of Cinacalcet HCl Data |
| April 9, 2003 |
NPS and Enzon Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger |
| March 24, 2003 |
NPS and Enzon File Registration Statement on Form S-4 |
| March 11, 2003 |
NPS Pharmaceuticals Second Annual Investor/Analyst Meeting 2003 |
| February 27, 2003 |
NPS Pharmaceuticals Reports Fourth Quarter and Year End 2002 Financial Results; Comments on Merger With Enzon |
| February 26, 2003 |
NPS Pharmaceuticals Provides Update of Progress With PREOS(TM) and Cinacalcet HCL |
| February 24, 2003 |
NPS Pharmaceuticals to Report Fourth Quarter and Year-End Operating Results |
| February 20, 2003 |
NPS Pharmaceuticals and Enzon Pharmaceuticals Agree to Merger of Equals |
| February 6, 2003 |
NPS Pharmaceuticals Provides Clinical Update |
| January 21, 2003 |
NPS Pharmaceuticals Introduces Redesigned Website |
| January 16, 2003 |
NPS Compound, PREOS(TM), Tested in Space |
| October 30, 2002 |
NPS Announces Conclusion of Financing, Deactivation of Shelf Registration |
| October 25, 2002 |
NPS Pharmaceuticals Prices Public Offering of Common Stock |
| October 21, 2002 |
NPS Pharmaceuticals Provides Corporate Update, Reports Third Quarter 2002 Operating Results |
| October 18, 2002 |
NPS Pharmaceuticals Revises Date to Report Third Quarter and Nine Month Operating Results |
| October 18, 2002 |
NPS Pharmaceuticals to File Preliminary Prospectus Supplement for 4,000,000 Share Public Offering |
| October 17, 2002 |
NPS Pharmaceuticals Appoints Stephen R. Parrish Vice President, Manufacturing |
| October 17, 2002 |
NPS Pharmaceuticals to Report Third Quarter and Nine Month Operating Results |
| September 30, 2002 |
NPS Completes 'Power' Study Enrollment |
| August 15, 2002 |
NPS Reports Interim PREOS Carcinogenicity Results |
| July 23, 2002 |
NPS Pharmaceuticals Reports Successful Production of PREOS, Second Quarter 2002 Operating Results |
| July 16, 2002 |
NPS Pharmaceuticals Announces Conference Call and Webcast of PREOS Manufacturing Update and Second Quarter 2002 Operating Results |
| July 3, 2002 |
NPS Pharmaceuticals Announces Appointment of Gerard Michel as Vice President, Corporate Development |
| June 12, 2002 |
NPS Pharmaceuticals Conference Call Replay Information |
| June 11, 2002 |
NPS Pharmaceuticals Announces Conference Call |
| June 11, 2002 |
NPS Update on Preos Manufacturing |
| June 10, 2002 |
NPS Pharmaceuticals to Present at Goldman, Sachs Healthcare Conference |
| May 20, 2002 |
Governor’s Medal Awards For Science And Technology Recipients Announced |
| May 8, 2002 |
NPS Pharmaceuticals Reports First Quarter 2002 Results |
| May 8, 2002 |
NPS Pharmaceuticals Announces Conference Call and Webcast Of First Quarter 2002 Operating Results |
| April 24, 2002 |
NPS Pharmaceuticals Announces Conference Call and Webcast Of First Quarter 2002 Operating Results |
| March 26, 2002 |
NPS Pharmaceuticals Reports Progress in Osteoporosis and Short Bowel Syndrome Clinical Trials |
| March 22, 2002 |
NPS Pharmaceuticals to Host Webcast on Current Research Programs In Osteoporosis, Gastrointestinal and CNS Disorders |
| February 5, 2002 |
NPS Pharmaceuticals Reports Fourth Quarter And Year End 2001 Financial Results; Clinical Program Update |
| February 4, 2002 |
NPS Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter And Full Year 2001 Operating Results |
| January 22, 2002 |
NPS Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter And Full Year 2001 Operating Results |
| January 7, 2002 |
NPS Pharmaceuticals Intends to File Shelf Registration Statement |
| December 20, 2001 |
Amgen and NPS Pharmaceuticals Announce Initiation of a Phase 3 Trial of a Calcimimetic in the Treatment of Secondary Hyperparathyroidism |
| November 26, 2001 |
NPS Pharmaceuticals Expands ALX1-11 Clinical Program |
| November 8, 2001 |
NPS Pharmaceuticals Reports Third Quarter And Nine Month 2001 Operating Results |
| November 8, 2001 |
NPS Pharmaceuticals Receives Milestone From Janssen for Potential Schizophrenia Treatment |
| November 1, 2001 |
NPS Pharmaceuticals Earns Milestone From Forest Laboratories for Migraine Program |
| October 29, 2001 |
NPS Pharmaceuticals Expands Commercial Organization With Executive Appointments |
| October 25, 2001 |
NPS Pharmaceuticals Announces Conference Call On Third Quarter 2001 Operating Results |
| October 18, 2001 |
Positive Phase II Data on Calcimimetics Reported at Medical Meetings |
| August 7, 2001 |
NPS Pharmaceuticals Reports Second Quarter And Six Month 2001 Operating Results |
| May 30, 2001 |
NPS Pharmaceuticals Executive Receives Utah's Innovator Award |
| May 14, 2001 |
NPS Pharmaceuticals Reports First Quarter 2001 Operating Results and Pipeline Progress |
| March 28, 2001 |
NPS Pharmaceuticals Announces R&D and Marketing Collaboration With AstraZeneca |
| February 21, 2001 |
NPS Pharmaceuticals Reports Fourth-Quarter and Year-End Operating Results |
| December 12, 2000 |
NPS Pharmaceuticals Announces Clinical Testing of Calcilytics By Its Partner SmithKline Beecham; Milestone Payment Earned |
| November 15, 2000 |
NPS Pharmaceuticals Closes Public Offering |
| November 10, 2000 |
NPS Pharmaceuticals Prices Public Offering |
| November 7, 2000 |
NPS Pharmaceuticals Reports Third-Quarter and Nine-Month Operating Results |
| October 13, 2000 |
NPS Pharmaceuticals Files Registration Statement for Common Stock Offering |
| August 29, 2000 |
NPS Pharmaceuticals Signs License Agreement With Forest Laboratories for Migraine Treatment |
| August 10, 2000 |
NPS Pharmaceuticals Reports Second-Quarter And Six-Month Operating Results |
| August 1, 2000 |
NPS Pharmaceuticals Receives Orphan Drug Status For ALX-0600 as Treatment for Short Bowel Syndrome |
| July 11, 2000 |
NPS Pharmaceuticals Added to Russell 3000 Index |
| July 5, 2000 |
Tamar Howson Joins NPS Pharmaceuticals's Board of Directors |
| June 28, 2000 |
Preliminary Data Support Further Development Of NPS 1776 for Neurological Disorders |
| May 18, 2000 |
UCSF to Coordinate Large Clinical Trial of New Osteoporosis Therapy |
